GlassScriptPhysician profile
Vinayak Ramanath
NPI 1356571079
$25,837.93
in general payments reported to CMS, 2019-2025
34 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $158 · 2021: $550 · 2022: $10K · 2023: $13K · 2024: $475 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $1,511 · Education: $187 · Consulting Fee: $82.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,488.00 |
| Food and Beverage | $1,511.34 |
| Education | $186.93 |
| Consulting Fee | $82.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23,291.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $783.89 | 2019-2025 | Farxiga, Lokelma |
| Baxter Healthcare | $273.01 | 2019-2024 | Renal - Pd, Renal - Acute |
| Travere Therapeutics, INC. | $174.29 | 2020-2025 | Filspari |
| Amgen INC. | $155.47 | 2019-2025 | Parsabiv, Tavneos, Aranesp |
| Mallinckrodt Hospital Products INC. | $142.11 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $119.69 | 2024-2025 | |
| Akebia Therapeutics INC | $119.63 | 2019-2025 | Vafseo, Auryxia |
| Valeritas, INC. | $90.00 | 2019 | |
| Glaxosmithkline, LLC. | $82.44 | 2022-2023 | Benlysta, Jesduvroq |
| Amarin Pharma, INC. | $81.47 | 2019 | |
| Novo Nordisk INC | $63.26 | 2024-2025 | Ozempic, Rybelsus |
| Medtronic Vascular, INC. | $61.43 | 2019 | |
| Fresenius USA Marketing, INC. | $51.44 | 2019-2024 | |
| Ardelyx, INC. | $50.79 | 2023-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $44.66 | 2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $41.22 | 2021-2025 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $35.51 | 2024 | Oxlumo |
| Cormedix INC. | $34.24 | 2024 | Defencath |
| Daiichi Sankyo INC. | $24.51 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2024 | Jardiance |
| Vifor Pharma, INC. | $22.73 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.61 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $18.16 | 2022 | |
| Horizon Therapeutics Plc | $17.64 | 2022 | |
| Neurelis, INC. | $17.04 | 2023 | Valtoco |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinayak Ramanath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.